DEPARTMENT OF VETERANS AFFAIRS
Veterans Health Administration
National Health Physics Program
2200 Fort Roots Drive
North Little Rock, AR 72114

JUL 22 2008

In Reply Refer To: 598/115HP/NLR

Cassandra F. Frazier
Division of Nuclear Material Safety
U.S. Nuclear Regulatory Commission, Region III
2443 Warrenville Road, Suite 210
Lisle, Illinois 60532-4352

Re: NRC License 03-23853-01VA

Dear Ms. Frazier,

I am forwarding the enclosed report regarding Event Number 44219. The report addresses two medical events that occurred at the VA Medical Center, Philadelphia, Pennsylvania, and is submitted pursuant to 10 CFR 35.3045(d). The medical center holds VHA Permit Number 37-00062-07 under our master material license.

A medical event involving two patients was reported to the NRC Operations Center on July 10, 2008. The event involved permanent implant prostate seed brachytherapy.

My staff performed the initial on-site part of a reactive inspection on May 28-29, 2008, and returned on June 24-25, 2008, to evaluate the circumstances of the events, assess initial actions to prevent a recurrence, and assess regulatory compliance. This inspection remains open. At the exit meeting on May 29, 2008, the inspectors asked the medical center to review a sample of additional brachytherapy treatments. This review by the medical center has revealed additional patient procedures that might be medical events. The NRC Operations Center was notified of these additional possible medical events on June 6, 12, 21, 25, and July 2, 8, 10, 15, and 18, 2008, as amendments to Event Number 44219. This report addresses two of these additional possible medical events.

If you have any questions, please contact me at (501) 257-1571.

Sincerely,

E. Lynn McGuire
Director, National Health Physics Program

Enclosure

Potential Medical Event - NRC Event Number 44219 Addendum

Notification of a possible medical event per 10 CFR 35.3045:

A brachytherapy procedure in which the administered dose may differ from the prescribed dose by more than 0.5 gray to an organ and the total dose delivered may differ from the prescribed dose by 20% or more.

VA Master Materials License **NRC License No. 03-23853-01VA**

Permittee: VA Medical Center, Philadelphia, PA

Date(s) of Event(s): See IMPLANT DATES below

Date Discovered: July 9, 2008

Date Reported to NHPP: July 10, 2008

Date Reported to NRC: July 10, 2008

Name of Prescribing Physician: Gary Kao, M.D., Ph.D.

Patient XRT #	Implant Date	Original CT Date	# Seeds Recovered	Original * Post Plan	Repeat CT	Re-Contour Date	Repeat Rx Plan
025	5-7-07	5-8-07	0	See Note *	6-25-08	7-3-08	7-7-08
031	10-2-06	10-3-06	0	See Note *	6-26-08	7-3-08	7-7-08

* Original CT scan data could not be retrieved. Patients scheduled for repeat CT in June, 2008

Description of the Event:

Two permanent prostate brachytherapy implant procedures were performed using Iodine-125 seeds on the dates listed above. The activity per seed and number of seeds prescribed in the written directives and used in the original treatment plans were ordered, received and implanted Efforts to retrieve CT scans for the above 2 patients were not successful. Patients were scheduled for CT scans in June, 2008. These were re-contoured and post-treatment plans were run. The D90 doses for the above 2 patients were significantly lower (more than -20%) than the planned prostate D90 dose.

As per the nomogram shared with NHPP, VACO, and Dr Giri, Chief, National VA Radiation Oncology Program, the above medical events are confirmed based on recently obtained repeat CT scans.

On July 9, 2008, the RSO and Chief of Radiation Oncology Service reviewed the results for the above patients and determined Medical Events had occurred. On 7-10-08, the RSO notified NHPP of these findings. The data for these patients is being reviewed as part of the causal analysis currently in process. Any necessary procedural changes will be implemented to prevent a recurrence before any additional brachytherapy procedures are performed. The brachytherapy program was formally put on-hold in early June, 2008.

Why the Event Occurred:
Root causes of event are still under investigation.

Effect on Patient:
Effect on patient is still under review.

Corrective Actions:
- Program is on–hold pending results of investigation
- QA program for Radiation Oncology is under review

Patient notification:
On July 9 and 10, 2008, the Chief of Radiation Oncology Service phoned the above 2 patients and their referring physicians/ primary care providers. Patients and referring physicians, and/or primary care providers, were informed the patients received a lower than planned prostate dose, the patients cases were being reviewed externally by an expert to obtain treatment option recommendations, and that the patients were entitled to receive a written report of the event.

JAMES E. CARY
CANCER CENTER

P.O. Box 551
5985 Hospital Drive
Hannibal, MO 63401
(573) 406-5800

CONFIDENTIAL

FACSIMILE TRANSMISSION

This facsimile may contain Protected Health Information that is of a sensitive and confidential nature. It is being faxed to you with the authorization of the patient or under circumstances where authorization is not required. You are required to maintain this information in a secure and confidential manner and are prohibited from re-disclosing it without first obtaining the patient's consent or as otherwise permitted by law. Unauthorized re-disclosure may subject you to federal and state law penalties.

IMPORTANT WARNING: This message is intended for the use of the person or entity to which it is addressed and may contain information that is confidential or privileged, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this information is strictly prohibited. If you have received this message by error, please notify us immediately at the number listed below and destroy the related message.

To: USNRC, Region III
Fax #: 630-515-1078
From: Dave DeProspero
Subject: Add "AMP"

Date: 7-22-08
Pages: 2 (including cover sheet)
Sender Telephone # 573-406-5801
Sender Fax #

COMMENTS:

Date: 22 July 2008

To: United States Nuclear Regulatory Commission, Region III
2443 Warrenville Road, Suite 210
Lisle, Illinois 60532-4352

From: David DeProspero, MA
James E. Cary Cancer Center
P.O. Box 551
Hannibal, MO. 63401

Subject: Add Authorized Medical Physicist (AMP) to NRC License No. 24-32681-01, Docket No. 030-37750

Please add Willis Brumley, M.S. to our license as an AMP for Iridium-192 in a High Dose Rate Remote Afterloading Brachytherapy device, and for calibrations, spot checks and training. Our license number is listed in the subject line above.

Mr. Brumley is currently listed as an AMP on USNRC License No. 24-32604-01, Docket No. 030-37082.

Thank you for your attention to this matter. If you have questions regarding this request I may be reached at the address listed above or by phone at 573-406-5801.

Sincerely,

David DeProspero, MA
Director, James E. Cary Cancer Center